AVIEW Lung Nodule CAD vs EchoNext
AI Verdict
Choose AVIEW Lung Nodule CAD if…
Choose AVIEW Lung Nodule CAD if your radiology department requires AI-powered assistance for comprehensive lung cancer screening, including the detection and analysis of pulmonary nodules (3-20mm) on chest CT scans. This tool is also ideal for simultaneously assessing COPD and coronary artery calcification, offering a 'Big 3' analysis from a single examination to streamline workflows and generate Lung-RADS compliant reports.
View AVIEW Lung Nodule CAD →Choose EchoNext if…
Choose EchoNext if your practice aims to leverage standard ECGs for early, non-invasive detection of hidden structural heart diseases like heart failure, valve disease, and pulmonary hypertension. This AI tool is particularly well-suited for broad screening in various clinical settings, from major hospitals to community practices, to identify high-risk patients who may require further cardiac evaluation.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW Lung Nodule CAD | EchoNext |
|---|---|---|
| Pricing | Contact for pricing | Starts at $600/month |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEW Lung Nodule CADAVIEW Lung Nodule CAD offers deployment flexibility (cloud, hybrid, local) and integrates with PACS, suggesting adaptability to various clinical workflows. It also generates automatic reports based on Lung-RADS classification and provides 3D visualization, which can enhance radiologist efficiency and patient communication. EchoNext is available through the OpenEvidence platform, which is used by many physicians, suggesting ease of access for existing OpenEvidence users, but its direct usability features are less detailed.
Clinical Value
EchoNextEchoNext has demonstrated superior diagnostic accuracy compared to cardiologists in detecting structural heart disease from ECGs, even when cardiologists were AI-assisted. It has also been credited with identifying previously undiagnosed heart failure that led to a heart transplant, highlighting its potential for early, life-saving intervention. AVIEW Lung Nodule CAD shows high sensitivity in nodule detection and can reduce reading time, but EchoNext's ability to detect conditions often missed by human interpretation and its direct impact on patient outcomes give it an edge in clinical value.
Pricing & Value
EchoNextEchoNext provides transparent tiered pricing starting at $600/month, with discounts for annual commitments and clear details on implementation fees. AVIEW Lung Nodule CAD's pricing is not publicly disclosed, requiring direct contact for information. While both offer potential cost savings through improved diagnostics, EchoNext's transparent and accessible pricing structure makes it easier for potential buyers to assess its value proposition.
Enterprise Readiness
AVIEW Lung Nodule CADAVIEW Lung Nodule CAD offers multiple deployment options (cloud, hybrid, local, virtualized) and has received FDA 510(k) clearance renewal after meeting strengthened cybersecurity criteria, indicating robust enterprise-grade security and flexibility. It is also used in government-led lung cancer screening projects across multiple countries. EchoNext is FDA-cleared and HIPAA compliant, and is available through the OpenEvidence platform, which is used by many US physicians, suggesting broad accessibility. However, AVIEW's diverse deployment options and explicit cybersecurity renewal demonstrate a more comprehensive approach to enterprise readiness.
Innovation
TieBoth tools demonstrate significant innovation in their respective fields. EchoNext is the world's first FDA-cleared AI tool to detect hidden structural heart disease from standard ECGs, a breakthrough in early cardiac screening. AVIEW Lung Nodule CAD offers simultaneous analysis of lung nodules, emphysema, and coronary artery calcification from a single CT scan ('Big 3'), providing a comprehensive screening approach. Given the unique and impactful nature of both innovations, it's a tie.
Support & Docs
TieNeither product's provided information or web search results offer extensive details on their support and documentation. Both are FDA-cleared, implying a certain level of regulatory documentation. Without further specific information on user manuals, training programs, customer support channels, or developer resources, it is not possible to definitively pick a winner.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW Lung Nodule CAD | EchoNext |
|---|---|---|
| Name | AVIEW Lung Nodule CAD | EchoNext |
| Company | Coreline Soft Co. | Pathway Labs |
| Description | AVIEW Lung Nodule CAD is an AI-powered software by Coreline Soft Co. that assists radiologists in detecting and analyzing pulmonary nodules on chest CT scans, and offers comprehensive screening for lung cancer, COPD, and coronary artery artery calcification. | EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Features | AI-based pulmonary nodule detection (3-20 mm) on CT scans; Nodule classification (solid, part-solid, non-solid); 3D nodule size and volume quantification; Automatic report generation based on Lung-RADS classification; Nodule matching and volume doubling time (VDT) calculation for follow-up comparisons; Simultaneous analysis of lung nodules, emphysema, and coronary artery calcification (Big 3); Quantitative emphysema analysis (e.g., Low Attenuation Area - LAA, emphysema index); Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass scores) | AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support |
Videos
Demos, reviews, and walkthroughs featuring AVIEW Lung Nodule CAD and EchoNext.